Early genetic screening for Alzheimer's disease
This test indicates the likelihood of developing Alzheimer's in the future.
How can we help you?
Non-obligation guidance
What is it?
This genetic screening is a method to evaluate the predisposition to develop the disease by analysing specific genes. Specifically, APOE genotyping is performed to detect the presence or absence of the E4 allele. This information can help doctors make more accurate decisions about treatment and prevention.
What is its cause?
Alzheimer's is a complex neurodegenerative disease with multiple causes. While genetics plays an important role, it is not the only determinant. Age, family history, lifestyle or other diseases may contribute to its development.
What is its incidence?
Alzheimer's disease is the most common form of dementia, and its incidence increases with age. It is estimated that around 5% of people over the age of 65 have Alzheimer's disease, and this percentage rises to almost 50% in people over the age of 85.
How is it diagnosed?
Diagnosis of Alzheimer's disease is based on a comprehensive clinical assessment including memory, thinking and language tests. In some cases, brain imaging and blood tests may also be performed.
How this study helps the medical specialist?
Patients carrying the E4 allele in the APOE gene have a risk three times higher than non-carriers, and in those with two copies, the risk is 12 times higher.
Studying the genetics of Alzheimer's disease can help clinicians:
- Identify people at higher risk of developing the disease.
- Better understand the disease and its causes.
- Develop new treatments and prevention strategies.
In which cases is it indicated?
Genetic testing for Alzheimer's may be indicated in the following people:
- People with a family history of Alzheimer's disease.
- People who have concerns about their memory or cognitive capacity.
- People participating in clinical trials for new treatments for Alzheimer's disease.
It is important to note that the Alzheimer's genetic test is not a definitive test for the disease. It only indicates the likelihood of developing Alzheimer's in the future.
Author: Dr Belén Lledó